A Human FcgRIIa (H131 variant)-specific Reporter Assay for Evaluating Antibody Activity in Antibody-dependent Phagocytosis ADCP Pathway Activation
Part # PS225
Teresa Surowy, Rich Moravec, Denise Garvin, Aileen Paguio and Frank Fan
R&D, Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711, USA
We describe here our development and evaluation of a human FcgRIIa (H131 variant)-specific reporter bioassay for quantifying antibody bioactivity in ADCP pathway activation. The H131 variant is able to bind all human IgG isotypes. The assay uses dual-engineered Jurkat effector cells that express the receptor and mediate FcgRIIa–dependent NFAT activation of reporter luciferase expression only when receptors are bound by target cell-bound antibodies.
Printed in USA 9/2014.